Doctors | Skin Cancer | Skin Medicine | Cosmetic

Non-Surgical Treatment of Non-Melanoma Skin Cancer

Doctor-led options for selected superficial basal cell carcinoma (sBCC) and Bowen’s disease (SCC in situ) — including laser-assisted photodynamic therapy, Efudix, and Aldara.

Book now to discuss your options [Book a 20 minute appointment with Dr Chris]

Key Takeaways

Surgery is not always required: Suitability for non-surgical care depends on the cancer type, depth, and location, often confirmed via biopsy (1, 4).
Advanced Alternatives: If you are considering Efudix or Aldara, laser-assisted photodynamic therapy (LA-PDT) is a highly effective in-clinic alternative that often involves significantly less at-home downtime with increased cure rates (10-14).
Exceptional Outcomes: Non-surgical pathways, particularly LA-PDT, can deliver excellent cosmetic results while maintaining high clearance rates for appropriate lesions (1,2,3,10-14).
Diagnosis First: We always prioritise safety, recommending histology (biopsy) when it is the most reliable way to guide your treatment plan.

Jump Links

Which non-melanoma skin cancers can be treated non-surgically?

Non-surgical treatment is generally reserved for selected superficial cancers, most commonly:

Superficial Basal Cell Carcinoma (sBCC)
Squamous Cell Carcinoma in situ (SCCis, also known as Intraepidermial Carcinoma (IEC) or Bowen’s disease)
Nodular Basal Cell Carcinoma (nBCC): Specifically via advanced protocols like LA-PDT*.

Suitability depends on a professional assessment of the lesion’s depth, site (high-risk areas may require surgery), your medical history, and your personal priorities regarding cosmesis and downtime (1, 4).

If you are unsure of a lesion, the first step is always a professional skin check.

See: Skin Cancer

[Book a 20 minute appointment with Dr Chris]

*nBCC indication for LA-PDT is sometimes considered an “off-label treatment” depending on depth histology and other clinical factors.

How we choose the safest option

We follow a rigorous clinical decision path:

Confirm the Diagnosis: Clinical examination and dermoscopy, followed by biopsy/histology if there is any uncertainty.
Assess Appropriateness: Determine if the lesion is thin or superficial enough for non-surgical methods.
Select the Pathway: We weigh clearance rates, recurrence risk, and cosmetic outcomes against your lifestyle and preferences.

Treatment Comparison: At-a-Glance

Feature	LA-PDT (Laser-Assisted)	Efudix (5-fluorouracil)	Aldara (imiquimod)
Indicated For	sBCC, SCCis, nBCC* (10-15)	SCCis (3)	sBCC (2)
Effectiveness	~94% – 100% ((10-14))	70% (8)	~80% (non-facial); 42–76% (facial) (9)
Delivery	In-clinic, doctor-led	At-home, self-applied (3)	At-home, self-applied (2)
Typical Course	1–2 sessions	Twice daily for 6 weeks	5 days a week for 6 weeks
Mechanism	Laser ablation + light-activated cell death	Topical chemotherapy (3)	Immune system stimulant (2)
Visible Reaction	Red, weeping area	Red, weeping area	Red, weeping area
Systemic (whole body) side effects	None	5-10% can develop flu like illness, abdominal cramps, persistent vomiting, bloody diarrhoea, alopecia, rare bone marrow suppression. Very rarely life threatening (18,19).	5-10% can develop Flu like illness, headaches, dizziness, insomnia, diarrhoea(16,17,19).
Discontinuation before treatment complete due to severe side effects	None	5% (19)	3% (19)
Downtime	Short (days)	Prolonged (weeks- two months)	Prolonged (weeks-two months
Cosmetic Outcome	Excellent (10-14)	Good (risk of pigment changes)	Good (risk of pigment changes)

*nBCC indication for LA-PDT may be considered off-label depending on clinical selection (36).

Detailed Efficacy of LA-PDT by Cancer Type

The “micro-channeling” and precise ablation combined with PDT used in this pathway allow for significantly higher success rates than traditional methods: (10-14)

Superficial BCC (sBCC): Near-perfect outcomes, with studies showing up to 100% clearance and long-term recurrence-free rates of 97.1%.
SCC in situ (Bowen’s Disease): Highly effective, with 93.8% clearance
Nodular BCC (nBCC): Exceptionally high success for a non-surgical method, reaching a 98.97% cure rate when laser ablation is combined with PDT.

Treatment Options in Detail

1) Laser-Assisted Photodynamic Therapy (LA-PDT)

LA-PDT is an advanced alternative that many patients find more convenient than long topical courses. It combines precise laser ablation of the visible tumour with light-activated targeted cell death to “mop up” any remaining cancerous cells.

The Process: The cancer is first precisely ablated with an erbium laser. Following this a fractional laser creates microscopic “wells” in the skin (the tumour bed as well as normal appearing margin) to enhance drug penetration, followed by a photosensitising cream and red LED light activation.
The Advantage: It is a doctor-led, in-clinic session that avoids weeks of self-application and delivers potentially surgery-level clearance with superior cosmetic results (10-14). See: Laser-assisted photodynamic therapy for non-melanoma skin cancer

2) Efudix (5-fluorouracil cream)

A prescription chemotherapy cream applied at home (3). It is effective for treating “fields” of damaged skin but requires a strict daily regimen and causes a prolonged inflammatory reaction as abnormal cells are cleared (1,16,17,19). See: Efudix

3) Aldara (imiquimod cream)

An immune-response modifier that stimulates your body’s own defences to attack the cancer (2). Like Efudix, it requires 6+ weeks of application and typically involves significant localized skin irritation during the treatment phase (2, 9, 18,19). See: Aldara

When surgery is safer

Non-surgical treatment is not appropriate when there is high risk or a need for absolute margin control (1, 4). Surgery can be safer if:

The cancer is high risk, either due to location or histology
Prior non-surgical treatments have failed.

FAQs

Is non-surgical treatment as effective as surgery? For selected superficial cancers, success rates are very high—up to 100% in some LA-PDT cases (10-15). However, surgery remains the gold standard for deeper lesions (or lesions that have the potential to metastasise – like invasive Squamous Cell Carcinoma or Melanoma) because it allows a pathologist to verify that all margins are clear(1, 4).

Why consider LA-PDT over Efudix or Aldara? LA-PDT is completed in-clinic, removing the need for 6 weeks of daily cream application. Healing usually occurs within a few days , whereas creams can cause visible inflammation for a month or more (1,2,3,4).

Will I need a biopsy first? Often, yes. Biopsy helps us confirm the exact type and depth of the cancer, ensuring we are performing the safest and most effective treatment for you(1,4).

Book Your Assessment

The first step toward non-surgical treatment is a comprehensive assessment to confirm your diagnosis and discuss the best personalised treatment for you.